surgoncoКреативная хирургия и онкологияCreative surgery and oncology2076-30932307-0501Башкирский государственный медицинский университет10.24060/2076-3093-2020-10-4-330-338surgonco-537Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWSРоль генетических мутаций в профилактике злокачественных новообразований у здорового населения (обзор литературы)The Role of Genetic Mutations in the Prevention of Malignant Tumours in a Healthy Population (A Review)https://orcid.org/0000-0002-8867-504XЛипатовО. Н.LipatovO. N.https://orcid.org/0000-0003-0773-1239АхметгарееваК. Т.AkhmetgareevaK. T.Республиканский клинический онкологический диспансерРоссияRepublican Clinical Oncological DispensaryRussian FederationРеспубликанский клинический онкологический диспансер;
Башкирский государственный медицинский университетРоссияRepublican Clinical Oncological Dispensary;
Bashkir State Medical UniversityRussian Federation202030122020104330338Copyright © Липатов О.Н., Ахметгареева К.Т., 20202020Липатов О.Н., Ахметгареева К.Т.Lipatov O.N., Akhmetgareeva K.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgonco.ru/jour/article/view/537злокачественные новообразованияпрофилактикагенетическая предрасположенность к болезнигенетическое тестированиемутагенности тестыгены EGFRгены BRCA1гены BRCA 2гены TP53гены RETмикросателлитная нестабильностьmalignant neoplasmspreventiongenetic susceptibility to diseasegenetic testingmutagenicity testsEGFR genesBRCA1 genesBRCA 2 genesTP53 genesRET genesmicrosatellite instabilityReferencesКаприн А.Д., Старинский В.В., Шахзадова А.О. Cостояние онкологической помощи населению России в 2019 году. М.: МНИОИ им. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020.Kaprin A.D., Starinsky V.V., Shakhzadova A.O. State of cancer care for population in Russia in 2019. Moscow: National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 2020 (In Russ.).Sokolenko A.P., Imyanitov E.N. Molecular diagnostics in clinical oncology. Front Mol Biosci. 2018;5:76. DOI: 10.3389/fmolb.2018.00076Sokolenko A.P., Imyanitov E.N. Molecular diagnostics in clinical oncology. Front Mol Biosci. 2018;5:76. DOI: 10.3389/fmolb.2018.00076Cancer: Fact Sheet No 297. WHO [cited 2015 March 20]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/Cancer: Fact Sheet No 297. WHO [cited 2015 March 20]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/Lichtenstein P., Holm N.V., Verksalo P.K., Iliadou A., Kaprio J., Koskenvuo M., et al. Environmental and heritable factors in the causation of cancer-analyses of cohort of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.Lichtenstein P., Holm N.V., Verksalo P.K., Iliadou A., Kaprio J., Koskenvuo M., et al. Environmental and heritable factors in the causation of cancer-analyses of cohort of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.Sultanbaev A., Nasretdinov A., Sultanbaeva N., Minniakhmetov I., Menshikov K., Musin S. 12P EGFR gene mutations landscape at lung cancer in a multinational region located in the southeast of the European part of Russia. Ann Oncol. 2020;31(Suppl. 5):S1220–1. DOI: 10.1016/j.annonc.2020.08.2171Sultanbaev A., Nasretdinov A., Sultanbaeva N., Minniakhmetov I., Menshikov K., Musin S. 12P EGFR gene mutations landscape at lung cancer in a multinational region located in the southeast of the European part of Russia. Ann Oncol. 2020;31(Suppl. 5):S1220–1. DOI: 10.1016/j.annonc.2020.08.2171Sultanbaev A., Nasretdinov A., Menshikov K., Sultanbaeva N., Musin Sh. Spectrum of mutations of epidermal growth factor genes in patients with lung cancer in the Republic of Bashkortostan. In: 46th Annual Meeting of Korean Cancer Association & 6th International Cancer Conference. Seoul, 2020. P. 188.Sultanbaev A., Nasretdinov A., Menshikov K., Sultanbaeva N., Musin Sh. Spectrum of mutations of epidermal growth factor genes in patients with lung cancer in the Republic of Bashkortostan. In: 46th Annual Meeting of Korean Cancer Association & 6th International Cancer Conference. Seoul, 2020. P. 188.Hemminki K., Dong C., Vaittinen P. Cancer risks to spouses and offspring in the family-cancer database. Genet Epidemiol. 2001;20(2): 247–57. DOI: 10.1002/1098-2272(200102)20:2<247::AIDGEPI7>3.0.CO;2-UHemminki K., Dong C., Vaittinen P. Cancer risks to spouses and offspring in the family-cancer database. Genet Epidemiol. 2001;20(2): 247–57. DOI: 10.1002/1098-2272(200102)20:2<247::AIDGEPI7>3.0.CO;2-UYamamoto H., Higasa K., Sakaguchi M., Shien K., Soh J., Ichimura K., et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Can Inst. 2014;106(1):djt3382014. DOI: 10.1093/jnci/djt338Yamamoto H., Higasa K., Sakaguchi M., Shien K., Soh J., Ichimura K., et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Can Inst. 2014;106(1):djt3382014. DOI: 10.1093/jnci/djt338Bell D.W., Gore I., Okimoto R.A., GodinHeymann N., Sordella R., Mulloy R., et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 2005;37(12):1315–6. DOI: 10.1038/ng1671Bell D.W., Gore I., Okimoto R.A., GodinHeymann N., Sordella R., Mulloy R., et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 2005;37(12):1315–6. DOI: 10.1038/ng1671Oxnard G.R., Miller V.A., Robson M.E., Azzoli C.G., Pao W., Ladanyi M., et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol. 2012;7(6):1049–52. DOI: 10.1097/JTO.0b013e318250ed9dOxnard G.R., Miller V.A., Robson M.E., Azzoli C.G., Pao W., Ladanyi M., et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol. 2012;7(6):1049–52. DOI: 10.1097/JTO.0b013e318250ed9dИмянитов Е.Н. Роль молекулярно-генетической диагностики в практической онкологии. Практическая онкология. 2019;20(4):261–73. DOI: 10.31917/2004261Imyanitov E.N. The role of molecular genetic diagnosis in clinical oncology. Practical oncology. 2019;20(4):261–73 (In Russ.). DOI: 10.31917/2004261Султанбаев А.В, Насретдинов А.Ф., Гордиев М.Г., Пушкарев А.В., Мусин Ш.И., Султанбаева Н.И. и др. Персонифицированный подход в ранней диагностике и профилактике злокачественных новообразований. Тезисы. VI Петербургский международный онкологический форум «Белые ночи 2020». Санкт-Петербург, 2020. 111 с.Sultanbaev A.V., Nasretdinov A.F., Gordiev M.G., Pushkarev A.V., Musin Sh.I., Sultanbaeva N.I., et al. Personalized approach to early diagnosis and prevention of malignant neoplasms. Abstracts. VI St. Petersburg International Oncology Forum “White Nights 2020”. Saint Petersburg; 2020. 111 p. (In Russ.).Gonzalez-Angulo A.M., Timms K.M., Liu S., Chen H., Litton J.K., Potter J., et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–9. DOI: 10.1158/1078-0432.CCR-10-2560Gonzalez-Angulo A.M., Timms K.M., Liu S., Chen H., Litton J.K., Potter J., et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–9. DOI: 10.1158/1078-0432.CCR-10-2560Насретдинов А.Ф., Султанбаева Н.И., Мусин Ш.И., Пушкарев А.В., Меньшиков К.В., Пушкарев В.А. и др. Уровень опухоль-инфильтрирующих лимфоцитов и PD- статус как возможные прогностические маркеры выживаемости и эффективности терапии при трижды негативном раке молочной железы. Опухоли женской репродуктивной системы. 2020;16(1):65–70. DOI: 10.17650/1994-4098-2020-16-1-65-70Nasretdinov A.F., Sultanbaeva N.I., Musin S.I., Pushkarev A.V., Menshikov K.V., Pushkarev V.A., et al. Level of tumor-infiltrating lymphocytes and PD status as potential prognostic markers of survival and therapy effectiveness in triple-negative breast cancer. Tumors of female reproductive system. 2020;16(1):65–70 (In Russ.). DOI: 10.17650/1994-4098-2020-16-1-65-70Prat J., Ribé A., Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005;36(8):861–70. DOI: 10.1016/j.humpath.2005.06.006Prat J., Ribé A., Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005;36(8):861–70. DOI: 10.1016/j.humpath.2005.06.006Мусин Ш.И., Султанбаева Н.И., Насредтинов А.Ф., Пушкарев А.В., Пушкарев В.А., Меньшиков К.В. и др. Определение высокопенетрантных мутаций у больных раком молочной железы. Norwegian Journal of development of the International Science. 2020;(42-2):56–9.Musin S.H., Sultanbaeva N., Nasretdinov A., Pushkarev A., Pushkarev V., Menshikov K., et al. Determination of high penetrant mutations in breast cancer patients. Norweg J Develop Int Sci. 2020; (42-2):56–9 (In Russ.).Липатов О.Н., Султанбаева Н.И., Меньшиков К.В., Султанбаев А.В. Опыт определения мутаций в гене PIK3CA у больных раком молочной железы в Республике Башкортостан. Злокачественные oпухоли. 2020;10(3 Suppl. 1). DOI: 10.18027/2224-5057Lipatov O.N., Sultanbaeva N.I., Menshikov K.V., Sultanbaev A.V. Experience in detecting PIK3CA mutations in patients with breast cancer in the Republic of Bashkortostan. Malignant tumors. 2020;10(3 Suppl. 1) (In Russ.). DOI: 10.18027/2224-5057Antoniou A.C., Casadei S., Heikkinen T., Barrowdale D., Pylkäs K., Roberts J., et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506. DOI: 10.1056/NEJMoa1400382Antoniou A.C., Casadei S., Heikkinen T., Barrowdale D., Pylkäs K., Roberts J., et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506. DOI: 10.1056/NEJMoa1400382Султанбаев А.В., Меньшиков К.В., Султанбаева Н.И., Мусин Ш.И., Минниахметов И.Р. Организация скрининга рака предстательной железы и носителей герминативных мутаций в генах BRCA1/2. Материалы XV международного конгресса Российского общества онкоурологов. М., 2020. С. 52.Sultanbaev A.V., Menshikov K.V., Sultanbaeva N.I., Musin S.I., Minniakhmetov I.R. Management of screening of prostate cancer and carriers with mutations of the BRCA1/2 genes. Proceedings of the XV international Congress of the Russian Society of Urologic oncologists. Moscow; 2020. P. 52 (In Russ.).Sultanbaev A., Nasretdinov A., Sultanbaeva N., Menshikov K., Musin S., Izmailov A., et al. Hereditary prostate cancer screening. Eur Urol Open Sci. 2020;21(Suppl 3):S155. DOI: 10.1016/S2666-1683(20)36212-1Sultanbaev A., Nasretdinov A., Sultanbaeva N., Menshikov K., Musin S., Izmailov A., et al. Hereditary prostate cancer screening. Eur Urol Open Sci. 2020;21(Suppl 3):S155. DOI: 10.1016/S2666-1683(20)36212-1Sultanbaev A., Menshikov K., Sultanbaeva N., Nasretdinov A., Minniakhmetov I., Musin S., et al. Organization of screening for prostate cancer in carriers of germinal mutations in the BRCA1 / 2 genes. Eur Urol Open Sci. 2020;21(Suppl 3):S59. DOI: 10.1016/S2666-1683(20)36064-XSultanbaev A., Menshikov K., Sultanbaeva N., Nasretdinov A., Minniakhmetov I., Musin S., et al. Organization of screening for prostate cancer in carriers of germinal mutations in the BRCA1 / 2 genes. Eur Urol Open Sci. 2020;21(Suppl 3):S59. DOI: 10.1016/S2666-1683(20)36064-XAxilbund J.E., Wiley E.A. Genetic testing by cancer site: pancreas. Cancer J. 2012;18(4):350–4. DOI: 10.1097/PPO.0b013e3182624694Axilbund J.E., Wiley E.A. Genetic testing by cancer site: pancreas. Cancer J. 2012;18(4):350–4. DOI: 10.1097/PPO.0b013e3182624694Samadder N.J., Baffy N., Giridhar K.V., Couch F.J., Riegert-Johnson D. Hereditary cancer syndromes-a primer on diagnosis and management, Part 2: gastrointestinal cancer syndromes. Mayo Clin Proc. 2019;94(6):1099–116. DOI: 10.1016/j.mayocp.2019.01.042Samadder N.J., Baffy N., Giridhar K.V., Couch F.J., Riegert-Johnson D. Hereditary cancer syndromes-a primer on diagnosis and management, Part 2: gastrointestinal cancer syndromes. Mayo Clin Proc. 2019;94(6):1099–116. DOI: 10.1016/j.mayocp.2019.01.042Carrera S., Sancho A., Azkona E., Azkuna J., Lopez- Vivanco G. Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract. 2017;15:9. DOI: 10.1186/s13053-017-0069-6Carrera S., Sancho A., Azkona E., Azkuna J., Lopez-Vivanco G. Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract. 2017;15:9. DOI: 10.1186/s13053-017-0069-6ten Broeke S.W., Brohet R.M., Tops C.M., van der Klift H.M., Velthuizen M.E., Bernstein I., et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol. 2015;33(4):319–25. DOI: 10.1200/JCO.2014.57.8088ten Broeke S.W., Brohet R.M., Tops C.M., van der Klift H.M., Velthuizen M.E., Bernstein I., et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol. 2015;33(4):319–25. DOI: 10.1200/JCO.2014.57.8088Waller A., Findeis S., Lee M.J. Familial adenomatous polyposis. J Pediatr Genet. 2016;5(2):78–83. DOI: 10.1055/s-0036-1579760Waller A., Findeis S., Lee M.J. Familial adenomatous polyposis. J Pediatr Genet. 2016;5(2):78–83. DOI: 10.1055/s-0036-1579760Talseth-Palmer B.A. The genetic basis of colonic adenomatous polyposis syndromes. Hered Cancer Clin Pract. 2017;15(1):5. DOI: 10.1186/s13053-017-0065-xTalseth-Palmer B.A. The genetic basis of colonic adenomatous polyposis syndromes. Hered Cancer Clin Pract. 2017;15(1):5. DOI: 10.1186/s13053-017-0065-xJelsig A.M., Qvist N., Brusgaard K., Nielsen C.B., Hansen T.P., Ousager L.B. Hamartomatous polyposis syndromes: a review. Orphanet J Rare Dis. 2014;9:101. DOI: 10.1186/1750-1172-9-10128 Jelsig A.M., Qvist N., Brusgaard K., Nielsen C.B., Hansen T.P., Ousager L.B. Hamartomatous polyposis syndromes: a review. Orphanet J Rare Dis. 2014;9:101. DOI: 10.1186/1750-1172-9-101Tavusbay C., Acar T., Kar H., Atahan K., Kamer E. The patients with Peutz-Jeghers syndrome have a high risk of developing cancer. Turk J Surg. 2018;34(2):162–4. DOI: 10.5152/turkjsurg.2017.3241Tavusbay C., Acar T., Kar H., Atahan K., Kamer E. The patients with Peutz-Jeghers syndrome have a high risk of developing cancer. Turk J Surg. 2018;34(2):162–4. DOI: 10.5152/turkjsurg.2017.3241Valdez J.M., Nichols K.E., Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. Br J Haematol. 2017;176(4):539–52. DOI: 10.1111/bjh.14461Valdez J.M., Nichols K.E., Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. Br J Haematol. 2017;176(4):539–52. DOI: 10.1111/bjh.14461Correa H. Li-Fraumeni Syndrome. J Pediatr Genet. 2016;5(2):84–8. DOI: 10.1055/s-0036-1579759Correa H. Li-Fraumeni Syndrome. J Pediatr Genet. 2016;5(2):84–8. DOI: 10.1055/s-0036-1579759McBride K.A., Ballinger M.L., Killick E., Kirk J., Tattersall M.H., Eeles R.A., et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. 2014;11(5):260–71. DOI: 10.1038/nrclinonc.2014.41McBride K.A., Ballinger M.L., Killick E., Kirk J., Tattersall M.H., Eeles R.A., et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. 2014;11(5):260–71. DOI: 10.1038/nrclinonc.2014.41Bougeard G., Renaux-Petel M., Flaman J.M., Charbonnier C., Fermey P., Belotti M., et al. Revisiting Li- Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33(21):2345–52. DOI: 10.1200/JCO.2014.59.5728Bougeard G., Renaux-Petel M., Flaman J.M., Charbonnier C., Fermey P., Belotti M., et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33(21):2345–52. DOI: 10.1200/JCO.2014.59.5728Mai P.L., Best A.F., Peters J.A., DeCastro R.M., Khincha P.P., Loud J.T., et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673–81. DOI: 10.1002/cncr.30248Mai P.L., Best A.F., Peters J.A., DeCastro R.M., Khincha P.P., Loud J.T., et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673–81. DOI: 10.1002/cncr.30248Fortuno C., James P., Spurdle A.B. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Hum Mutat. 2018;39(12):1764–73. DOI: 10.1002/humu.23656Fortuno C., James P., Spurdle A.B. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Hum Mutat. 2018;39(12):1764–73. DOI: 10.1002/humu.23656Zhang K., Zhou J., Zhu X., Luo M., Xu C., Yu J., et al. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer. Breast Cancer Res Treat. 2017;166(3):865–73. DOI: 10.1007/s10549-017-4425-zZhang K., Zhou J., Zhu X., Luo M., Xu C., Yu J., et al. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer. Breast Cancer Res Treat. 2017;166(3):865–73. DOI: 10.1007/s10549-017-4425-zNorton J.A., Krampitz G., Jensen R.T. Multiple endocrine neoplasia: genetics and clinical management. Surg Oncol Clin N Am. 2015; 24(4): 795–832. DOI: 10.1016/j.soc.2015.06.008Norton J.A., Krampitz G., Jensen R.T. Multiple endocrine neoplasia: genetics and clinical management. Surg Oncol Clin N Am. 2015; 24(4): 795–832. DOI: 10.1016/j.soc.2015.06.008Goudet P., Dalac A., Le Bras M., Cardot-Bauters C., Niccoli P., Lévy-Bohbot N., et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568–77. DOI: 10.1210/jc.2014-3659Goudet P., Dalac A., Le Bras M., Cardot-Bauters C., Niccoli P., Lévy-Bohbot N., et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568–77. DOI: 10.1210/jc.2014-3659Norton J.A., Kinz P.L. Multiple endocrine neoplasias. In: DeVita V.T., Lawrence T.S., Rosenberg S.A. (editors). Cancer: Principles and Practice of Oncology. LWW; 2015. P. 1227–34.Norton J.A., Kinz P.L. Multiple endocrine neoplasias. In: DeVita V.T., Lawrence T.S., Rosenberg S.A. (editors). Cancer: Principles and Practice of Oncology. LWW; 2015. P. 1227–34.Eng C. Multiple endocrine neoplasia type 2. 1999 Sep 27 [updated 2019 Aug 15]. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J.H., Stephens K., et al. (editors). GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993–2020. PMID: 20301434Eng C. Multiple endocrine neoplasia type 2. 1999 Sep 27 [updated 2019 Aug 15]. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J.H., Stephens K., et al. (editors). GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993–2020. PMID: 20301434Tomuschat C., Puri P. RET gene is a major risk factor for Hirschsprung’s disease: a meta-analysis. Pediatr Surg Int. 2015;31:701–10. DOI: 10.1007/s00383-015-3731-yTomuschat C., Puri P. RET gene is a major risk factor for Hirschsprung’s disease: a meta-analysis. Pediatr Surg Int. 2015;31:701–10. DOI: 10.1007/s00383-015-3731-yRajagopala S.V., Vashee S., Oldfield L.M., Suzuki Y., Venter J.C., Telenti A., et al. The human microbiome and cancer. Cancer Prev Res (Phila). 2017;10(4):226–34. DOI: 10.1158/1940-6207.CAPR-16-0249Rajagopala S.V., Vashee S., Oldfield L.M., Suzuki Y., Venter J.C., Telenti A., et al. The human microbiome and cancer. Cancer Prev Res (Phila). 2017;10(4):226–34. DOI: 10.1158/1940-6207.CAPR-16-0249Garrett W.S. Cancer and the microbiota. Science. 2015;348:80–6. DOI: 10.1126/science.aaa4972Garrett W.S. Cancer and the microbiota. Science. 2015;348:80–6. DOI: 10.1126/science.aaa4972Zhang J., Walsh M.F., Wu G., Edmonson M.N., Gruber T.A., Easton J., et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336–46. DOI: 10.1056/NEJMoa1508054Zhang J., Walsh M.F., Wu G., Edmonson M.N., Gruber T.A., Easton J., et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336–46. DOI: 10.1056/NEJMoa1508054University of Chicago Hematopoietic Malignancies Cancer Risk Team. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016;128(14):1800–13. DOI: 10.1182/blood-2016-05-670240University of Chicago Hematopoietic Malignancies Cancer Risk Team. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016;128(14):1800–13. DOI: 10.1182/blood-2016-05-670240Poggi M., Canault M., Favier M., Turro E., Saultier P., Ghalloussi D., et al. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. Haematologica. 2017;102(2):282–94. DOI: 10.3324/haematol.2016.147694Poggi M., Canault M., Favier M., Turro E., Saultier P., Ghalloussi D., et al. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. Haematologica. 2017;102(2):282–94. DOI: 10.3324/haematol.2016.147694Melazzini F., Palombo F., Balduini A., De Rocco D., Marconi C., Noris P., et al. Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica. 2016;101(11):1333–42. DOI: 10.3324/haematol.2016.147496Melazzini F., Palombo F., Balduini A., De Rocco D., Marconi C., Noris P., et al. Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica. 2016;101(11):1333–42. DOI: 10.3324/haematol.2016.147496Hyde R.K., Liu P.P. Germline PAX5 mutations and B cell leukemia. Nat Genet. 2013;45(10):1104–5. DOI: 10.1038/ng.2778Hyde R.K., Liu P.P. Germline PAX5 mutations and B cell leukemia. Nat Genet. 2013;45(10):1104–5. DOI: 10.1038/ng.2778Swaminathan M., Bannon S.A., Routbort M., Naqvi K., Kadia T.M., Takahashi K., et al. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019;5(1):a003210. DOI: 10.1101/mcs.a003210Swaminathan M., Bannon S.A., Routbort M., Naqvi K., Kadia T.M., Takahashi K., et al. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019;5(1):a003210. DOI: 10.1101/mcs.a003210
The authors declare that there are no conflicts of interest present.